Giese v. Pierce Chemical Co.

29 F. Supp. 2d 33, 49 U.S.P.Q. 2d (BNA) 1498, 1998 U.S. Dist. LEXIS 21362, 1998 WL 856576
CourtDistrict Court, D. Massachusetts
DecidedDecember 2, 1998
DocketCivil Action 97-12561-WGY
StatusPublished
Cited by8 cases

This text of 29 F. Supp. 2d 33 (Giese v. Pierce Chemical Co.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Giese v. Pierce Chemical Co., 29 F. Supp. 2d 33, 49 U.S.P.Q. 2d (BNA) 1498, 1998 U.S. Dist. LEXIS 21362, 1998 WL 856576 (D. Mass. 1998).

Opinion

MEMORANDUM AND ORDER

YOUNG, District Judge.

The plaintiff, Roger W. Giese, commenced suit against the defendants, Vector Laboratories, Inc. (“Vector”) and Pierce Chemical Co. (“Pierce”), alleging contributory infringement and inducement of infringement of Giese’s patents, United States Letters Patent Nos. Re.31,712 (“the ’712 Patent”) and Bl,4,478,-914 (“the ’914 Patent”).

The patents cover a method by which multiple layers of chemicals are attached to one another to form a stable system. The resulting system typically is used to improve detection of certain types of cells, for example, cancer cells. Vector manufactures a kit of chemical reagents marketed under the trade name “Vectastain ABC Kit”, a product designed to assist in the marking and detection of various types of cells. Pierce purchases' the kits for subsequent resale. Giese maintains in his Amended Complaint that the ABC Kits “incorporate the technology dis *35 covered by the Plaintiff.” Amended Complaint ¶ 9. Giese further alleges that the defendants use “a component of Dr. Giese’s patented technology in its ABC Staining Kits which component constitutes a material part of Dr. Giese’s invention.” Amended Complaint ¶ 15. On the strength of these allegations, Giese contends that both Vector and Pierce have contributed to or have actively induced the direct infringement of the patents. Giese includes no count for direct infringement.

Vector and Pierce come now before this Court with three separate motions for summary judgment. The first seeks partial summary judgment on the ground of non-infringement as to certain end users of the kits. The second is based on the doctrine of laches. The third asserts equitable estoppel. For the sake of clarity, this memorandum will address each motion separately.

I. NON-INFRINGEMENT

The defendants’ first motion for summary judgment asserts non-infringement under the common law experimental use exception to patent infringement. See Roche Prods., Inc. v. Bolar Pharmaceutical Co., 733 F.2d 858 (Fed.Cir.1984). It is undisputed that a substantial portion of the ABC kits are sold to non-profit institutional, educational, and academic researchers. As to this portion of sales, the defendants seek summary judgment that there can be no contributory infringement or active inducement liability. The argument may be stated simply: there can be no contributory infringement or active inducement without direct infringement; there has been no direct infringement because academic researchers under certain circumstances are permitted to engage in activities that would otherwise constitute infringement; therefore there has been no contributory infringement or active inducement.

A. Facts

The facts underlying this motion are undisputed, but not well developed. The parties agree that a substantial portion of the ABC kits are sold to academic researchers, but there is no agreement on exactly what proportion, and no information at all as to which users fall into that category. 1 It is also undisputed that the sales literature states that the kits are designed to be used for research purposes only.

Further, Vector concedes that some of its sales are to commercial users, and does not seek summary judgment as to those users. Vector also concedes that it sells kits to Pierce, which then resells them. As to those kits, Vector argues that Pierce does not practice the patented methods, and that any infringement must be based on infringement by end users who do practice the patented methods without permission. Vector, invoking the same syllogism it applies to its own direct sales to consumers, argues that only commercial users purchasing from Pierce may infringe.

B. Analysis

The experimental use exception to the patent infringement provisions of 35 U.S.C. § 271 has its origins in the notion that “it could never have been the intention of the legislature to punish a man, who constructed ... a [patented] machine merely for philosophical experiments .... ” Whittemore v. Cutter, 29 F. Cas. 1120 (C.C.D.Mass.1813)(No. 17,600)(Story, J.). In the intervening years, the doctrine has been the subject of considerable discussion but infrequent application. See Suzanne T. Michel, The Experimental Use Exception to Infringement Applied to Federally Funded Inventions, 7 High Tech. L.J. 369, 371-73 (1992); Ned A. Israelsen, Making, Using, and Selling Without Infringing: an Examination of 35 U.S.C. Section 271(e) and the Experimental Use Exception to Patent Infringement, 16 AIPLA Q.J. 457, 458-62 (1989). The most authoritative discussion appears in the Federal Circuit’s Roche decision. In Roche, the court described the exception as “truly nar *36 row,” excluding from its scope the use of a patented invention “ ‘in keeping with the legitimate business of the [alleged infringer].’ ” Id., 733 F.2d at 863 (quoting Pitcairn v. United States, 547 F.2d 1106, 1125-26 [Ct.Cl.1976]). The court held that the defendant’s experimental use was “solely for business reasons and not for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry,” id., and thus was not exempted from infringement.

Roche established a restrictive definition of the traditional common law doctrine, but in no way eliminated it in those cases which involve experimentation for “idle curiosity or for strictly philosophical inquiry.” Id. Giese does not dispute that the doctrine applies in some instances, yet because the record contains no information about the actual experimental use, this Court need not and cannot decide at this point whether any particular use falls within the exception.

Giese, however, challenges the application of the doctrine on a different ground: that Vector and Pierce profit from the sales of the kits, regardless of whether they are put to use for experimental purposes or for purely commercial purposes. That profit, asserts Giese, deprives Giese of a benefit which derives from the use of his patented processes, and thus should deprive the defendants of the shelter of the experimental use exception.

Giese’s analysis is flawed, and would allow him to protect rights beyond those conferred upon him by the patents. Both the ’712 and the ’914 patents are method patents. Infringement of a method patent consists of practicing the claimed methods; the materials used to practice the methods are not themselves protected. In order to prevail on a direct infringement claim, Giese would need to prove either that the kit is manufactured using the claimed methods, or that he owns a patent covering the material composition of the reagents in the kit. Giese makes no such claims.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Akamai Technologies, Inc. v. Limelight Networks, Inc.
692 F.3d 1301 (Federal Circuit, 2012)
Lautzenhiser Technologies, LLC v. Sunrise Medical HHG, Inc.
752 F. Supp. 2d 988 (S.D. Indiana, 2010)
McLain v. City of Somerville
424 F. Supp. 2d 329 (D. Massachusetts, 2006)
Vectra Fitness, Inc. v. Icon Health & Fitness, Inc.
288 F. Supp. 2d 1155 (W.D. Washington, 2003)
Roche Diagnostics Corp. v. Selfcare Inc.
233 F. Supp. 2d 1038 (S.D. Indiana, 2002)
Madey v. Duke University
266 F. Supp. 2d 420 (M.D. North Carolina, 2001)
Stein v. United States
135 F. Supp. 2d 265 (D. Massachusetts, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
29 F. Supp. 2d 33, 49 U.S.P.Q. 2d (BNA) 1498, 1998 U.S. Dist. LEXIS 21362, 1998 WL 856576, Counsel Stack Legal Research, https://law.counselstack.com/opinion/giese-v-pierce-chemical-co-mad-1998.